Published in Cancer Chemother Pharmacol on June 24, 2006
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer (2008) 0.91
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88
Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients (2013) 0.81
Grape seed extract dose-responsively decreases disease severity in a rat model of mucositis; concomitantly enhancing chemotherapeutic effectiveness in colon cancer cells. PLoS One (2014) 0.80
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Exp Biol Med (Maywood) (2015) 0.79
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). Cancer Biol Ther (2009) 1.39
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett (2005) 1.25
Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol (2011) 1.17
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00
Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev (2010) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
The role of capsule endoscopy in suspected celiac disease patients with positive celiac serology. Dig Dis Sci (2010) 0.93
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer (2014) 0.92
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol (2012) 0.91
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91
Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch (2009) 0.90
Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis. Crit Rev Food Sci Nutr (2011) 0.89
Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clin Proteomics (2011) 0.89
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer (2014) 0.89
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther (2009) 0.88
CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci (2007) 0.86
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85
Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol (2009) 0.85
Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer (2007) 0.85
Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. Support Care Cancer (2012) 0.85
Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85
Deficiency of invariant NK T cells in Crohn's disease and ulcerative colitis. Dig Dis Sci (2007) 0.85
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer (2014) 0.85
Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. Exp Biol Med (Maywood) (2013) 0.84
The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol (2002) 0.84
Mucositis guidelines: what have they achieved, and where to from here? Support Care Cancer (2006) 0.82
Deficiency of 6B11+ invariant NK T-cells in celiac disease. Dig Dis Sci (2007) 0.82
Predictors of acute adverse events from rapid rituximab infusion. Support Care Cancer (2013) 0.81
Fatty acids as potential adjunctive colorectal chemotherapeutic agents. Cancer Biol Ther (2011) 0.81
Emu oil increases colonic crypt depth in a rat model of ulcerative colitis. Dig Dis Sci (2011) 0.81
Maternal milk, but not formula, regulates the immune response to beta-lactoglobulin in allergy-prone rat pups. J Nutr (2009) 0.81
The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem! Cancer Biol Ther (2006) 0.80
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther (2007) 0.80
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs (2008) 0.80
Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs (2007) 0.80
Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther (2011) 0.80
The urgent need for an effective biomarker for cytotoxic therapy-induced adverse effects. Curr Opin Support Palliat Care (2013) 0.79
Wnt blockade with dickkopf reduces intestinal crypt fission and intestinal growth in infant rats. J Pediatr Gastroenterol Nutr (2012) 0.79
Severe mucositis: how can nutrition help? Curr Opin Clin Nutr Metab Care (2007) 0.79
Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev (2008) 0.78
Activation of beta-catenin in the stem cell region of crypts during growth of the small intestine in infant rats. Dig Dis Sci (2007) 0.78
Capsule endoscopy: a valuable tool in the follow-up of people with celiac disease on a gluten-free diet. Clin Transl Gastroenterol (2011) 0.78
Novel therapies. Semin Oncol Nurs (2004) 0.78